This week’s Conference on Retroviruses and Opportunistic Infections (CROI) has come at a timely moment in an intensifying battle between two players, in particular, for market share in the HIV space.
US biotech Gilead Sciences (Nasdaq: GILD) and Viiv Healthcare, the HIV specialist that is majority-owned by UK drugmaker GlaxoSmithKline (LSE: GSK), are battling not just in the courtroom, but also through data presentations showing the benefits of their therapies.
At CROI, Gilead has offered trial results to show the potential benefits of switching to its newly-approved triple therapy Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) from ViiV’s Triumeq (abacavir/dolutegravir/lamivudine), in virologically suppressed adults with HIV.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze